公开(公告)号：US20070099935A1

公开(公告)日：2007-05-03

申请号：US10581412

申请日：2004-12-03

Applicant: Christopher Burns ,  Andrew Wilks ,  Xianyong Bu

Inventor： Christopher Burns ,  Andrew Wilks ,  Xianyong Bu

IPC: A61K31/497 ,  C07D403/04 ,  C07D403/14

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

Abstract: A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating kinase-associated disease states using the compound of formula (I) is also described.

Abstract translation: 描述了通式（I）的化合物或其药学上可接受的前药，盐，水合物，溶剂合物，结晶形式或非对映异构体。 还描述了使用式（I）化合物治疗激酶相关疾病状态的方法。

公开(公告)号：US20070082894A1

公开(公告)日：2007-04-12

申请号：US10538499

申请日：2003-12-11

Applicant: Christopher Burns ,  Andrew Wilks ,  Xianyong Bu ,  Harrison Sikanyika ,  Michael Harte

Inventor： Christopher Burns ,  Andrew Wilks ,  Xianyong Bu ,  Harrison Sikanyika ,  Michael Harte

IPC: A61K31/541 ,  A61K31/5377 ,  A61K31/4965 ,  C07D417/02 ,  C07D413/02 ,  C07D403/02

CPC classification number: C07D405/12 ,  C07D241/20 ,  C07D401/12 ,  C07D405/04 ,  C07F9/650952

Abstract: A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating a hyperproliferation-related disease state or disorder in a subject using a compound of formula (I) is also described.

Abstract translation: 描述了通式（I）的化合物或其药学上可接受的前药，盐，水合物，溶剂合物，结晶形式或非对映异构体。 还描述了使用式（I）化合物治疗受试者的过度增生相关疾病状态或障碍的方法。

公开(公告)号：US20060148824A1

公开(公告)日：2006-07-06

申请号：US11367248

申请日：2006-03-02

Applicant: Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

Inventor： Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

IPC: A61K31/4965

CPC classification number: C07D401/12 ,  C07D241/20 ,  C07D405/12

Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms of diastereomers thereof is described. Method of inhibiting a protein kinase using compounds of Formula I are also described.

Abstract translation: 描述了以下通式的化合物或其药学上可接受的盐，水合物，溶剂合物，其非对映异构体的晶体形式。 还描述了使用式I化合物抑制蛋白激酶的方法。

公开(公告)号：US20060270687A1

公开(公告)日：2006-11-30

申请号：US11397982

申请日：2006-04-04

Applicant: Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

Inventor： Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

IPC: A61K31/497 ,  C07D403/04

CPC classification number: C07D401/14 ,  A61K31/497 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula I is also described.

公开(公告)号：US20050004140A1

公开(公告)日：2005-01-06

申请号：US10472156

申请日：2003-05-23

Applicant: Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

Inventor： Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

IPC: C07D241/20 ,  A61K31/497 ,  A61K31/5377 ,  A61P3/10 ,  A61P5/14 ,  A61P11/06 ,  A61P17/00 ,  A61P19/02 ,  A61P21/00 ,  A61P27/16 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07

CPC classification number: C07D401/14 ,  A61K31/497 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula I is also described.

Abstract translation: 描述了通式的化合物或其药学上可接受的盐，水合物，溶剂合物，结晶形式或非对映异构体。 还描述了使用式I化合物治疗蛋白激酶相关疾病状态的方法。

公开(公告)号：US20070161635A1

公开(公告)日：2007-07-12

申请号：US11711957

申请日：2007-02-27

Applicant: Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

Inventor： Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

IPC: A61K31/5377 ,  A61K31/497

CPC classification number: C07D401/14 ,  A61K31/497 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

Abstract: Methods using compounds of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof to treat protein kinase-associated disease states is described.

Abstract translation: 描述了使用以下通式的化合物或其药学上可接受的盐，水合物，溶剂合物，结晶形式或非对映异构体来治疗蛋白激酶相关疾病状态的方法。

公开(公告)号：US20060241112A1

公开(公告)日：2006-10-26

申请号：US11397973

申请日：2006-04-04

Applicant: Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

Inventor： Christopher Burns ,  Xianyong Bu ,  Andrew Wilks

IPC: A61K31/5377 ,  A61K31/497 ,  C07D413/14 ,  C07D403/02

CPC classification number: C07D401/14 ,  A61K31/497 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula I is also described.

公开(公告)号：US07122550B2

公开(公告)日：2006-10-17

申请号：US10469303

申请日：2003-05-23

Applicant: Christopher John Burns ,  Xianyong Bu ,  Andrew Frederick Wilks

Inventor： Christopher John Burns ,  Xianyong Bu ,  Andrew Frederick Wilks

IPC: A61K31/4965 ,  C07D241/00 ,  C07D241/02 ,  C07D401/00

CPC classification number: C07D401/12 ,  C07D241/20 ,  C07D405/12

Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms of diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of Formula I is also described.

Abstract translation: 描述了以下通式的化合物或其药学上可接受的盐，水合物，溶剂合物，其非对映异构体的晶体形式。 还描述了使用式I化合物治疗蛋白激酶相关疾病状态的方法。

公开(公告)号：US07737143B2

公开(公告)日：2010-06-15

申请号：US10581412

申请日：2004-12-03

Applicant: Christopher John Burns ,  Andrew Frederick Wilks ,  Xianyong Bu

Inventor： Christopher John Burns ,  Andrew Frederick Wilks ,  Xianyong Bu

IPC: C07D401/02 ,  C07D241/20 ,  C07D295/04 ,  A61K31/497 ,  A61K31/5355 ,  A61P29/00 ,  A61P25/28 ,  A61P9/00

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

Abstract: A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating kinase-associated disease states using the compound of formula (I) is also described.

Abstract translation: 描述了通式（I）的化合物或其药学上可接受的前药，盐，水合物，溶剂合物，结晶形式或非对映异构体。 还描述了使用式（I）化合物治疗激酶相关疾病状态的方法。

公开(公告)号：US20080207613A1

公开(公告)日：2008-08-28

申请号：US10585916

申请日：2005-01-12

Applicant: Michelle Leanne Styles ,  Jun Zeng ,  Herbert Rudolf Treutlein ,  Andrew Frederick Wilks ,  Marcel Robert Kling ,  Christopher John Burns ,  Xianyong Bu

Inventor： Michelle Leanne Styles ,  Jun Zeng ,  Herbert Rudolf Treutlein ,  Andrew Frederick Wilks ,  Marcel Robert Kling ,  Christopher John Burns ,  Xianyong Bu

IPC: A61K31/5377 ,  C07D403/04 ,  C07D403/14 ,  C07D401/04 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  A61P37/06 ,  C07D401/14 ,  C07D235/04 ,  A61K31/497 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/4184

CPC classification number: C07D403/04 ,  C07D235/30 ,  C07D241/20 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12

Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4 are optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I).

Abstract translation: 通式（I）的化合物或其药学上可接受的前药，盐，水合物，溶剂合物，结晶形式或非对映异构体，其中A表示多种六元含氮杂环，Q为键，卤素， 1-4烷基，O，S，SO 2，CO或CS和X 1，X 2，X _{3和X 4任选被9个特定取代基取代，或者可以是氮。 还提供了包含载体和至少一种式（I）化合物的组合物。 还提供了通过施用式（I）化合物和通过施用式（I）化合物来抑制受试者的免疫系统的方法来治疗酪氨酸激酶相关疾病状态的方法。}